Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
    4.
    发明申请
    Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors 审中-公开
    磺酰化吡咯-2-二氢吲哚酮衍生物作为激酶抑制剂

    公开(公告)号:US20050032871A1

    公开(公告)日:2005-02-10

    申请号:US10653470

    申请日:2003-09-03

    CPC分类号: C07D403/06 C07D413/14

    摘要: The present invention relates to compounds having the following chemical structure (Formula I): where the substituents R1-R10 are defined herein. The compounds of this invention are useful in treating disorders related to abnormal kinase activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

    摘要翻译: 本发明涉及具有以下化学结构(式I)的化合物:其中取代基R 1 -R 10在本文中定义。 本发明的化合物可用于治疗与异常激酶活性相关的疾病。 还公开了包含这些化合物的药物组合物,利用包含这些化合物的药物组合物治疗疾病的方法及其制备方法。

    Product line management system and method thereof
    6.
    发明授权
    Product line management system and method thereof 有权
    产品线管理系统及其方法

    公开(公告)号:US08805566B2

    公开(公告)日:2014-08-12

    申请号:US13040235

    申请日:2011-03-03

    IPC分类号: G06F19/00

    摘要: A method testing the quality of products applied to a system is provided. Each product includes a unique identification number. The system includes a data storage device and test devices. The data storage device includes a first table recording identification numbers, test types, and test results, each test device stores a second table records the identification numbers and the test types. The method includes: obtaining the identification number; obtaining the test type; determining whether a test type previous to the test type exists; and generating first information to prompt the operator to return the to-be-tested product to the workstation of previous test type when the test result corresponding to the existed previous test type does not exist or the test result corresponding to the existed previous test type is a first value.

    摘要翻译: 提供了一种测试应用于系统的产品质量的方法。 每个产品都包含唯一的识别号码。 该系统包括一个数据存储设备和测试设备。 数据存储装置包括记录识别号,测试类型和测试结果的第一表,每个测试设备存储第二表记录标识号和测试类型。 该方法包括:获取识别号码; 获得测试类型; 确定是否存在测试类型之前的测试类型; 并且当不存在与现有的先前测试类型相对应的测试结果或者与现有的测试类型相对应的测试结果是生成第一信息以提示操作者将待测试产品返回到先前测试类型的工作站 第一个值。

    Indolinone combinatorial libraries and related products and methods for the treatment of disease
    10.
    发明申请
    Indolinone combinatorial libraries and related products and methods for the treatment of disease 有权
    吲哚酮组合文库及相关产品及治疗方法

    公开(公告)号:US20050197382A1

    公开(公告)日:2005-09-08

    申请号:US10784917

    申请日:2004-02-24

    CPC分类号: C07D209/34

    摘要: The present invention relates to organic molecules capable of modulating, regulating and/or inhibiting protein kinase signal transduction. Such compounds are useful for the treatment of diseases related to unregulated protein kinase signal transduction, including cell proliferative diseases such as cancer, atherosclerosis, arthritis and restenosis and metabolic diseases such as diabetes. The present invention features indolinone compounds that potently inhibit protein kinases and related products and methods. Inhibitors specific to the FLK protein kinase can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone, in particular at the 1′ position of the indole ring. Indolinone compounds that specifically inhibit the FLK and platelet derived growth factor protein kinases can harbor a tetrahydroindole or cyclopentano-b-pyrrol moiety. Indolinone compounds that are modified with substituents, particularly at the 5 position of the oxindole ring, can effectively activate protein kinases. This invention also features novel hydrosoluble indolinone compounds that are tyrosine kinase inhibitors and related products and methods.

    摘要翻译: 本发明涉及能够调节,调节和/或抑制蛋白激酶信号转导的有机分子。 这些化合物可用于治疗与未调节的蛋白激酶信号转导相关的疾病,包括细胞增殖性疾病如癌症,动脉粥样硬化,关节炎和再狭窄以及诸如糖尿病的代谢疾病。 本发明具有抑制蛋白激酶及相关产物和方法的吲哚啉酮化合物。 可以通过向3 - [(吲哚-3-基)亚甲基] -2-二氢吲哚酮,特别是在吲哚环的1'位置添加化学取代基来获得对FLK蛋白激酶特异性的抑制剂。 特异性抑制FLK和血小板衍生生长因子蛋白激酶的吲哚酮化合物可以含有四氢吲哚或环戊基-b-吡咯部分。 被取代基修饰的吲哚啉酮化合物,特别是在羟吲哚环的5位,可以有效地激活蛋白激酶。 本发明还具有酪氨酸激酶抑制剂和相关产物和方法的新型水溶性吲哚啉酮化合物。